CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Vaxxinity, we, us or the Company) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Vaxxinity, we, us or the Company) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Vaxxinity Announces Positive Data from Phase 1 Trial for Parkinson™s Disease
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research...
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with...
Vaxxinity, an immunotherapeutic vaccine developer, is boldly going into partnership with the University of Central Florida to advance space medicine research.